Drug intelligence / Profile preview

attenuated MVA monkeypox vaccine

Development stage
Phase 1
Lead developer
Shanghai Institute of Biological Products
Modality
Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

The attenuated MVA monkeypox vaccine is a live-attenuated viral vaccine based on the Modified Vaccinia Ankara (MVA) strain, developed by the Shanghai Institute of Biological Products (SIBP), a subsidiary of Sinopharm (China National Biotec Group). MVA is a highly attenuated, non-replicating or poorly replicating orthopoxvirus that has been extensively used as a safe vaccine vector. This specific candidate is designed to prevent monkeypox (mpox) infection by inducing active immunity against the monkeypox virus. In clinical evaluation, it is administered via a two-dose subcutaneous schedule, with doses given 28 days apart. The vaccine is currently undergoing Phase I clinical trials in China to assess its safety and immunogenicity in adults.

Other names
MVA monkeypox attenuated live vaccineModified Vaccinia Ankara monkeypox vaccine减毒猴痘疫苗(MVA株)
02

Targets

OPXV MV/EEV antigens (Orthopoxvirus mature virion and extracellular enveloped virion surface antigens)

Beyond the preview

Go deeper on attenuated MVA monkeypox vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on attenuated MVA monkeypox vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call